KNOW YOUR COVID-19 VACCINES (data as of May 05, 2021)

Pfizer Oxford Sinovac Gamaleya Bharat

Moderna Novavax Janssen
BioNTech AstraZeneca CoronaVac Sputnik V BioTech
Technology viral vector viral vector viral vector
mRNA inactivated virus inactivated virus mrRNA protein subunit
Platform (non-replicating) (non-replicating) (non-replicating)
Philippine FDA EUA
January 14, 2021 January 28, 2021 February 22, 2021 March 19, 2021 April 19, 2021 May 5, 2021 - April 19, 2021
Approval [a]
Dose & Frequency 2 doses, 21 days apart [a] 2 doses, 4-12 weeks apart [a] 2 doses, 28 days apart [a] 2 doses, 3 weeks apart [a] 2 doses, 28 days apart [a] 2 doses, 28 days apart [b] 2 doses, 21 days apart [c] 1 dose [a]
Storage -18°C and below -25 to -15°C
-80 to -60°C [a] 2 to 8°C [a] 2 to 8°C [a] 2 to 8°C [a] 2 to 8°C [h] 2-8°C (3 months) [a]
Requirements (frozen solution) [a] 2 to 8°C (30 days) [e]
66.1-66.9% against
70-4% against asymptomatic 91.6% against symptomatic 94.1% against symptomatic confirmed moderate
Vaccine Efficacy 95% against COVID-19 [a] 65-91% (based on Brazil, COVID-19 [b] 80.6% against PCR- COVID-19 [b] awaiting Official Phase III to severe/critical
Based on Phase III asymptomatic COVID-19 Indonesia, and Turkey confirmed symptomatic Interim Journal COVID-19
Clinical Trial (CT) [b] 100% against severe Trials) [a] 100% against moderate or COVID-19 [e] 100% against severe Publication
COVID-19 [b] severe cases [b] COVID-19 [b] ~77-85% against
severe COVID-19 [j]
▪ pain on injection site
▪ hyperthermia
▪ swelling [b]
▪ pain, erythema, or swelling
▪ local lymphadenopathy ▪ headache
on injection site ▪ injection site pain
at injection site ▪ asthenia
▪ headache ▪ axillary lymphadenopathy ▪ redness
▪ injection site pain and ▪ allergic reaction that may ▪ muscle/joint pain
▪ short-term, mild-to- ▪ fatigue ▪ fever ▪ swelling
Common Adverse tenderness be caused by any ▪ malaise
moderate pain at ▪ fever ▪ headache awaiting Official Phase III ▪ tiredness
Events Reported ▪ fatigue component of the ▪ sore throat
injection site ▪ body ache ▪ fatigue Interim Journal ▪ headache
Observed in Phase ▪ headache vaccine (hives, allergic ▪ diarrhea
▪ fatigue ▪ abdominal pain ▪ myalgia Publication ▪ muscle pain
III CT ▪ feverishness rashes and purpura, ▪ rhinorrhea
▪ headache [b] ▪ nausea ▪ arthralgia ▪ chills
▪ myalgia [b] anaphylactic shock) ▪ loss of appetite
▪ vomiting [e] ▪ nausea ▪ fever
▪ convulsion (with or ▪ pain in the oropharynx
▪ vomiting ▪ nausea [g]
without fever) [i] ▪ nasal congestion
▪ chills [b]
▪ colds
▪ sneezing
▪ cough [b]
References: a. FDA Philippines EUA Approval b. Publication in Journals for Phase III Interim Results c. WHO Landscape and Tracker of COVID-19 Candidate Vaccines d. WHO Interim Recommendations for EUL e. Submission to FDA EUA Application f. Clinicaltrials.gov g.
Center for Disease Control and Prevention h. Publication in Journals for Phase 1 and/or Phase 2 CT results i. FDA Published Product Information Materials j. US FDA Published Vaccine Fact Sheets

AIRAH M.